SLC1A2 and amyotrophic lateral sclerosis: Downregulation of EAAT2 has been demonstrated in patients with Alzheimer’s disease (Jacob et al., 2007; Li et al., 1997) or amyotrophic lateral sclerosis (ALS) (Rothstein et al., 1995), as well as in ALS rodent models (Bendotti et al., 2001; Bruijn et al., 1997; Howland et al., 2002; Tong et al., 2013).